A double blind randomised placebo controlled phase III trial in patients with chronic idiopathic constipation to demonstrate the efficacy and safety of Elobixibat 5mgs & 10mgs for 26 wks (ECHO)
1st September 2013
Specialism: Lower GI.
Team: Professor Robin Spiller.
|Professor Robin Spiller||Robin's main interest is in the pathophysiology of functional GI diseases, particularly focusing on the role of infection and inflammation and alterations in serotonin metabolism in the irritable bowel syndrome. He has twice edited the British Society of…|